# Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season

> **NCT03688620** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1060 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **OTHER:** Passive enhanced safety surveillance

## Key facts

- **NCT ID:** NCT03688620
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-05
- **Primary completion:** 2019-01-04
- **Final completion:** 2019-01-04
- **Target enrollment:** 1060 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03688620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03688620, "Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03688620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*